Preclinical characterization of bemarituzumab, an anti-FGFR2b antibody for the treatment of cancer

Por Hong Xiang, Abigael G. Chan, Ago Ahene, David I. Bellovin, Rong Deng, Amy W. Hsu, Ursula Jeffry, Servando Palencia, Janine Powers, James Zanghi, Helen Collins
Publicado em 2021-01-01